## Index

Abbott Laboratories 38, 45–7  
abuse of process 231  
academic networks: Thailand 35–6, 42–3  
Act Up–Paris 46–7, 52  
Adamson, R.L. 82  
African Regional Intellectual Property Organization (ARIPO) 218  
Agreement on Trade-Related Aspects of Intellectual Property see TRIPS Agreement  
agro-biotech industries 16  
seeds see seeds, illicit  
AIDS see HIV/AIDS  
American Chambers of Commerce (AmChams) 16–17, 33, 46  
Andersen, B. 80  
animal varieties 211, 228  
Anuradha, R.V. 84  
Argentina 58, 61  
patents 13–15, 25–6  
strengthening interests 16–19  
weakening interests 19, 20–25  
auryapacha plant 80–81, 89, 92–3, 102  
benefit sharers, definition of 91  
benefit sharing agreement, impact of 93–6  
identifying the Kanis 96–100  
conclusion 101–2  
key questions 85–6  
lessons learnt 100  
Arrow, K.J. 3  
Artelsmair, G. 131, 132  
Arthur, W.B. 213  
Arya Vaidya Pharmacy (AVP) 92, 93, 95, 96  
_Astron Clinica Ltd and Others_ (2008) 219  
Atkinson, S. 219  
atorneys see lawyers  
Australia: patent ownership 183, 190, 191, 192, 204  
corporate patenting 192–201  
ownership of US patents 189–90  
winners, patent system 188  
Austria 147, 189–90  

Bakels, R.B. 186  
Bale, Harvey 29  
Barton, J.H. 186  
Bates, M. 191  
Bayer 69  
BBC 63, 74  
Beigbeder, Y. 1  
Beland, D. 225  
Belgium 147, 151, 189–90  
Benford, R.D. 109  
Bessen, J.E. 1, 3, 183, 184, 185, 186, 188, 204, 205, 227  
Bettig, R.V. 90, 176  
Bhatiasevi, A. 42  
Biehl, J. 20  
Bijoy, C.R. 86  
bilateral trade agreements (BTAs) 17, 30  
biodiversity 35  
Convention on Biological Diversity (CBD) 86, 87–8, 94  

conclusion 151–5  
‘economy’ frame: introduction of directive 133–4  
‘ethics’ frame: contestation of directive 134–6  
European Parliament, role of 137–9  
evaluation of 1998 outcome 142–5  
frame analysis 130–31  
frame constellation (1988–95) 136–7  
frame constellation (1995–98) 139–42
legislative outcomes 150–51
stem cells, human embryonic 145–7
biopiracy 82, 91–2
see also traditional knowledge
biosafety: transgenic seeds 56, 58, 59, 61–2, 68–9, 70, 73–5
Black, J. 137
Blakeney, M. 84
Bodoni, S. 231
Boldrin, M. 183, 185
Bolkestein, Frits 116, 117–18
Borrás, S. 132
Boseley, S. 42
Bouwen, P. 108
Boyce, Ralph 33–4
Boyd, S.L. 82
Boyle, J. 3, 154
Brazil 35, 48, 58, 59, 61
compulsory licences 21, 50
patents 13–15, 25–6
strengthening interests 16–19
weakening interests 19–25
breast cancer genes, patents on 140
Brethhauer, L. 160, 166
Brimelow, Alison 151
Bristol-Myers Squibb (BMS) 41–2, 52, 201
British Telecom 116
Brush, S.B. 89
Bt cotton see under India
Buena Vista 163
Burk, D.L. 153
Bush, George W. 32
business methods patents 205, 207, 222
Butler, J.P. 49
Byerlee, D. 82
Calestous, J. 81
Canada
patents 67, 189, 190, 195, 220
transgenic crops 57, 61
cancer drugs 34, 46, 48, 52
cancer genes, patents on 140
Caribbean 18
Cartagena Protocol 59
Chaiya Sasomsab 48
chemical sector/companies 16, 184, 188, 194, 195, 200, 201
Chennells, R. 80, 86
China 58, 59, 61
CII (Computer Implemented Inventions) see Software Patents Directive
Clinton, Bill 42, 47–8, 51
cloning 144
Cohen, J.I. 59, 61
Cohen, W.M. 184, 185–6
Cole, J.H. 185
compulsory licences 21
Thailand 29–31, 37, 48–9
Oct 2001: universal health cover 37–8
Jan 2006: mobilization 39–41
historical decision 41–3
Sept 2006: military coup 44
chain reaction 44–7
May 2007: diplomatic mission 47–8
players 32–7
use of 30, 50
computers/software sector 194, 200
see also software under patents
constitutional rights
medicines, access to 20, 21, 22, 25
Convention on Biological Diversity (CBD) 86, 87–8, 94
Cook, T. 80
copyright: digital movie industry see under Germany
Cornelli, F. 226
Cornish, W. 231
Correa, C.M. 1, 2, 29
cost–benefit analysis 221
cotton, Bt see under India
counterfeiting 110
seeds 56, 57, 58, 59, 62, 65, 66, 74
Cronin, D. 35
Cystic Fibrosis Association, Danish 141
David, P.A. 3, 84, 212
Davies, L. 222
Delta and Pine Land 60
Denmark 147
Denzau, A. 214


developed countries 49, 87, 222
asymmetrical power relationships 30, 48
IP, innovation and costs 24
see also individual countries
developing countries 87, 90
asymmetrical power relationships 30
foreign knowledge and technology 14
‘grow into’ IP regimes 23–5
pharmaceutical patents 31
Doha Declaration 30
TRIPS Agreement 19–20
research, transgenic crop 59
TRIPS agreement 19–20, 107–8
see also individual countries


DNA sequences and patents 135–6, 140, 142, 143–4, 146, 147–51, 152
incremental change 228
non-obviousness doctrine 232
Doberstyn, E.B. 42
Doern, G.B. 217
Doha Declaration 29–30, 34, 46, 47, 48
Drahos, P. 1, 2, 5, 16, 40, 107, 182, 200, 205, 218, 229
Dryzek, J. 130, 138
Du Pont 200
Ducor, P. 232
Dutfield, G. 80, 89, 135

Ebay 168
economics/economists 153, 154, 184, 215, 227, 229–30
Edwards, C.D. 187

EICTA (European Information & Communications Technology Industry Association) 114, 116, 121, 126

EISAI/Second Medical Use (1985) 223–4

Eisenberg, R. 223, 228
electronics/electrics industries 194, 195, 200

embryos
Biopatent Directive 143, 144, 145

human embryonic stem cells 145–7

Emmott, S. 131, 138
Enforcement Directive, IP 109–11
conclusion 123–4, 125–6
methodology: political claims
analysis 111–12
results 112–13
actors and actions 114–16, 118
framing 118–20

Ericsson 195

ETNO (European Telecommunications Network Operators Association) 116–17, 118, 120

Etro, F. 80

Europe 16
patents 67, 195, 211, 216, 222
EPC see European Patent Convention
EPO see European Patent Office

European AIDS Treatment Group (EATG) 47

European Alliance of Genetic Support Groups (EAGS) 140–41

European Central Bank v DSS (2008) 216

European Court of Justice (ECJ) 146, 147, 221

European Digital Rights Initiative (EDRi) 118

European Patent Convention (EPC) 110, 132–3, 135, 136, 147, 218
diagnostic methods 225–6
medical treatment, methods of 223–4
specific, substantial and credible standard (SSCS) 217

European Patent Litigation Agreement 221

European Patent Office (EPO) 132, 136, 146–7, 151, 154, 218
breast cancer genes 140
increasing returns 222–4, 225–6
incrementalism 228–9
inter-institutional linkages 217–19, 220, 221–2
quasi-judicial authority 215, 220
national courts 218
oncomouse 135, 220
Politics of intellectual property

stem cells
human embryonic 145–6
process for identifying 145
European Union 57, 166, 173, 218–19, 221, 233
framing processes
biopatents see Biopatent Directive
IP enforcement see Enforcement Directive, IP
software see Software Patents Directive
European Court of Justice (ECJ) 146, 147, 221
Thailand 33, 34, 35, 45
exporters: patents and Latin America 17
Finland 147
Fischer, F. 130
flea-markets 168
FMC 200
food industry 16
foreign investors: patents and Latin America 16–17
Fourtou, Janelly 117–18, 126
framing processes 6, 40, 51, 56
conclusion 123–6
conflicts about EU directives 109–11
biopatents see Biopatent Directive
definition of frame 111
GMO frame 58
introduction 107–9
methodology: political claims analysis 111–12
patent offices 215
patent system: incrementalism 229
results 112–14
actors and actions 114–18
framing 118–23
France 33, 35, 46–7, 48
Biopatent Directive 147, 150–51
patents 187
ownership of US and Australian 189, 190, 191, 195
political claims analysis 111, 112, 116, 117, 118
free trade agreements (FTAs) Thai–United States 30, 32, 35, 39–41, 50
G8 summit (2007) 107, 108
Gaisford, J.D. 81, 84, 87, 90
Gamson, W.A. 108
Gans, J.S. 226
gene sequences see DNA sequences
gene use restriction technology (GURT) 60, 75
General Electric 200, 201
General Motors 201
genetically engineered (GE) animals 228
oncomouse 135, 220
political framing of GMOs 56, 57, 58, 75
seeds see seeds, illicit
Gerhards, J. 109
Germany
digital movie industry 158–9
conclusion 174–7
hegemonic struggles: acceptance of IP law 167–70
materialist state theories 159–61
movie market 161–3, 178
movie production costs 178
non-licensed copying and re-regulation of IP law 163–7
public film funding law 158, 159, 162–3, 173–4, 175
relations of movie production and re-regulation of IP law 170–72
patents 193, 221
Biopatent Directive 145, 147, 148, 150–51
ownership of US and Australian 189, 190, 191, 195
winners, patent system 187
political claims analysis 111, 112, 116, 117, 118
Geron 146
Index

Gillespie-White, L. 91

globalization and knowledge paradigms 81–5

GMOs, political framing of 56, 57, 58, 75

Godt, C. 154, 155

Gold, A.G. 60

Gorlin, J. 108

Gottweis, H. 141

Gramsci, A. 158, 161, 167

grasses 75

Greaves, T. 88, 89

Greece 147

Greenpeace 138, 145

Greenwood, J. 108

Griffiths, W. 188

Griliches, Z. 187

Guellec, D. 153

Guennif, S. 42

Gupta, A.K. 59

Haas, P.M. 221

Habermas, J. 130

Hall, B.H. 205, 228

Hall, P.A. 213

Hamilton, C. 82

Harhoff, D. 188

Hathaway, O. 229

Haunss, S. 5, 112, 118, 125

health: access to medicines 13, 20–21, 22, 25, 185

compulsory licences see compulsory licences

Hein, W. 1, 109

Heinrich, S. 160

Heller, M.A. 148

Helpman, E. 3, 80

Henry, M.D. 220

Herring, R.J. 57, 58, 59, 60, 61, 63, 64, 65, 75

Hettinger, E.C. 3

Hewlett-Packard 201

Hilgartner, S. 60

Hitchcock, J. 221

HIV/AIDS 109

compulsory licences

Brazil 50

Thailand see Thailand: patents and public health

treatments 38, 41–2, 51

Hoechst 195

Hoodia plant 92, 98

Hope, J. 80

Hopkins, M. 146

Horrocks, S.M. 82, 88

human embryonic stem cells (hESCs) 145–7

human rights medicines, access to 20, 21, 22

patent law 142–3, 152

IBM 193, 200, 201

IFPI (International Federation of the Phonographic Industry) 118, 120

IFPMA (International Federation of Pharmaceutical Manufacturers and Associations) 29, 33

illicit seeds see seeds, illicit

import tariffs: Thai exports to US 51

increasing returns, dynamics of 5–6

patents see under patents

India 35, 48, 84

Kani tribe 81, 87, 92–3, 101–2

benefit sharing agreement 93–100

identifying the Kanis 96–100, 101

key questions 85–6

lessons learnt 100

patents 90

based on indigenous knowledge 83, 92, 93, 96, 98

research in biotechnology 59, 61

transgenic crops 61

Bt cotton 56, 58, 59, 61–6, 68–73, 74, 75

IP rights: plant varieties and seeds 67–8

mustard 69

indigenous people 80–81, 101–2

definitions 91–2

globalization and knowledge paradigms 81–5

Kani tribe 81, 87, 92–3, 101–2

benefit sharing agreement 93–100

identifying the Kanis 96–100, 101

key questions 85–6

lessons learnt 100

nation state and IPRs 86–91, 101

San tribe 92, 98, 101
industry in Thailand, local 36–7
information technology sector 195
Intel 201
‘intellectual property’, use of term 50
Internet
Act Up–Paris 46
Blackberry email service 231
movie industry 164, 165, 166, 167, 169, 170, 174, 175
transgenic seeds 74
Internet service providers 166
IPRED see Enforcement Directive, IP
Ireland 147
Israel 189–90
Italy 145, 146, 147, 151, 163

Jaffe, A.B. 183
Japan 16, 57, 131
patents 193
ownership of US and Australian 189, 190, 191, 194, 195, 201
patent office 218, 222
Jarothe, S. 163
Jayaraman, K.S. 59, 64
Jensen, A.K. 85
Jessop, B. 158, 160–61, 175
Johnson & Johnson 201, 207
Joshi, Sharad 63, 70

Kahin, B. 186
Kansa, E.C. 82, 84, 85, 86, 88, 89
Kapczynski, A. 14, 20
Karani, P. 80
Kazmin, A. 29
Kimberly-Clark 195
King, S.R. 91
Klingensmith, D. 89
Klug, H. 1
Knowledge Ecology International (KEI) (formerly CPTech) 36
Koesch, S. 168
Koopmans, R. 111, 112
Korea 193, 195, 201
Krasser, R. 150
Kreft, A.R. 133, 140
Krempl, S. 168
Krikorian, G.P. 39
Kuanpooth, J. 30
Kumar, N. 14
Kuttimathen Kani 81, 93, 94
Laird, S. 83
Lalitha, N. 67
Lamberton, D.M. 191
Landes, W.M. 183, 205, 215, 220, 227
Lanjouw, J.O. 229
Latin America
patents 13–15, 25–6
strengthening interests 16–19
weakening interests 19–25
lawyers
movie industry, German 166–7, 168
patents 131, 153, 186, 205
Latin America 17–18
Software Patents Directive 114, 115–16
Le Buanec, B. 67
Leith, P. 215, 223
Lemley, M. 3, 226
Lerner, J. 205
Levin, R.C. 184
light-manufacturing sector 17
Limpananont, J. 42
Lipton, M. 60
litigation, skewed nature of patent 229–32
Long, C. 227
Loypacher, L.J. 82
Lungren, Ex parte (2005) 224
Luxembourg 147, 151
Lybbert, T.J. 61

Macdonald, S. 184, 185
Mahyco Monsanto Biotech Ltd (MMBL) 62, 63, 64–5, 68–73, 75
maize, transgenic 58
Maltby, R. 162
Mandelson, Peter 33, 34, 35
Mansfield, E. 16, 184
market access 17
Martinez-Alier, J. 82
Marwell, G. 221
Marx, K. 159, 160, 170
Maskus, K.E. 1, 2, 81, 87
Matthews, D. 2, 5, 16
May, C. 1, 2, 14, 176
Mayntz, R. 130, 151
Mazzoleni, R. 184
Médecins Sans Frontières (MSF) 35, 36
Meier, H.E. 108
‘mental maps’ 125, 214, 225
Merck 38, 46
Merck Sharp & Dohme Ltd 200
Merges, R.P. 3, 226
Merrell Dow Pharmaceuticals v HN Norton (1996) 218
Mexico 58
patents 13–15, 25–6
strengthening interests 16–19
weakening interests 19, 20–25
Mgbeoji, I. 92
Micron Technologies 201
Microsoft 119, 126
military coup in Thailand 32, 44
Miller, H.I. 58, 59
Mohai, K.H. 80
Moir, H.V.J. 185, 191, 195, 200
Mongkol Na Songkhla 29, 43, 44, 47
Monsanto 57, 58, 59, 60, 61–2, 201
Moon, G. 80, 98
Morera, E. 161
Morocco 50
Morse 69
most-favored nation (MFN) access 17
movie industry, digital see under Germany
Müller, Florian 116
multinational companies see transnational corporations
Murray, F. 58
Murugkar, M. 72
mustard, GM 69
Musu, I. 87, 90
Myriad Genetics 140
Nack, R. 133
Naím, M. 61, 74
Nelson, R.R. 184
Netherlands 145, 146, 147
Newell, P. 82
Niebler, Angelika 117–18
Nit Phibunsonkhram 39
Nokia 116, 195
non-governmental organizations (NGOs) 20, 118, 138
indigenous people 84, 85, 98, 101–2
Thailand 35–6, 39–40, 42
transgenic crops 57, 59, 74
Nortel Networks 195
North, D.C. 213
Norway 146
Novartis 34
NTP, Inc v Research in Motion (2005) 231
Nuss, S. 160
Offe, C. 160
Olson, M. 182
oncomouse, Harvard 135, 220
organic farmers 60
Oxfam 36
Paarlberg, R.L. 57, 74
Pakes, A. 187, 188
Pakistan 61
Paramount 163
Parthasarathy, S. 140
Patel, Piyush 64
patents
biopatents 222
animal varieties 211, 228
Directive see Biopatent Directive
oncomouse 135, 220
plants 67, 82–4, 87
plants: indigenous knowledge of
India 83, 92, 93, 96, 98
empirical analysis: patent ownership
introduction 182–5
losers, patent system 185–7
priorities for further research 204–6
US and Australia 189–92
US and Australia: corporate patenting 190–91, 192–204
winners, patent system 187–9
increasing returns 211–13
conclusion 232–3
doctrinal incoherence 216–17
incrementalism and uncertainty 227–9
inter-institutional linkages 217–22
litigation, skewed nature of 229–32
patent offices, role of 222–7
sources and features 213–17
sub-optimal outcomes 215–17
timing, value of 214–15
India 83, 90, 92, 93, 96, 98
Politics of intellectual property

Latin America 13–15, 25–6
strengthening interests 16–19
weakening interests 19–25
software 6, 110, 186, 211, 219, 229
Directive see Software Patents Directive
specific, substantial and credible standard (SSCS) 217
see also Enforcement Directive, IP
path dependence 212, 214, 215, 227, 233
patients groups 20, 141
Pawar, Sharad 63
Penrose, E.T. 191
Pfizer 38, 80, 200
pharmaceutical patents 16, 184, 188
compulsory licences see compulsory licences
empirical analysis: Australian and US patent ownership 194, 195, 201
framing processes 109
India 90
Latin America 13, 15, 19–21, 22, 25
traditional knowledge 82, 89, 98
winners and losers, patent system 185, 188
see also Biopatent Directive
Philippines 38
PhRMA (Pharmaceutical Research and Manufacturers of America) 33, 42, 47
Pila, J. 229
plants
IP protection for plant varieties 67–8
traditional knowledge see traditional knowledge
see also seeds, illicit
Poland: political claims analysis 111–12, 116, 117
political claims analysis see framing processes
Portugal 147
Potrykus, I. 57
Poulantzas, N. 158, 160
Pray, C. 70
prosumers 4
public goods 215, 230
Pugatch, M. 1
Pushpangadan, P. 81, 92
Ragavan, S. 84
Rai, A.K. 146
Ramachandran, R. 42
Ramanjaneyulu, G.V. 60
Ramanna, A. 67
Ramawami, D. 71
Reber, N. 177
regional and bilateral trade agreements (RBTAs) 2, 17
Rein, M. 130
Remiche, B. 29
Renesse, M. von 150
reverse-engineering 14
Rhodia 207
rice 75
Richardson, J. 108
Rocard, Michel 116
Roche 46
Rockwell International 200
Rojas, M.C. 86
Roy, D. 59, 69
Ryan, M.P. 2, 5, 182
Saengsuree Joota 34
Samak Sundaravej 48
San tribe 92, 98, 101
Sanguan Nittayarumpong 43
Sarnsamak, P. 34
Sarup, M. 82
Sayer, A. 160
Schankerman, M. 187
Scherer, F.M. 182, 184, 201, 205
Schmeiser, Percy 57
Schneider, I. 132, 133, 144, 146, 147, 150, 151, 154, 155
Schön, D. 131
Schröder, C. 162
Schweiger, T. 141
scientific community 18, 21–3, 47
Scotchmer, S. 3, 226
seeds, illicit 56
conclusions 73–5
counterfeit seeds 58, 59, 62, 65, 66, 74
stealth seeds distinguished from 56, 57
Index

development: bio-safety and bio-property 60–62
introduction and overview 57–60
IP: farmers’ rights and breeders’ rights 66–8
transgenic cotton in India 56, 58, 59, 61–6, 74, 75
IP: farmers’ rights and breeders’ rights 67–8
stealth seeds, impact of 68–73

Searge, K. 176
Sell, S.K. 1, 2, 5, 16, 30, 40, 107, 108, 182, 205
Shadlen, K.C. 1, 2, 17, 21
Shah, E. 71
Shaji, K.A. 96, 98
Sherman, B. 212
Shiva, V. 61, 82, 84, 85, 89, 91
Silverbrook Research 200
Simeone, T. 84
Sirilak Suteekul 34
small and medium-sized enterprises (SMEs): framing processes
Biopatent Directive 134
Software Patents Directive 110, 114, 118, 121–2, 123, 124–5, 126
Smith, S.E. 90
SmithKline Beecham 141
Snow, D.A. 40, 108, 109, 111, 122
social movements 35, 50, 59
framing processes 108, 109
Software Patents Directive 109–11, 132
closure 123, 124–6
methodology: political claims
analysis 111–12
results 112, 113
actors and actions 114, 116–18
framing 118–19, 121–3
somatic cell nuclear transfer (SCNT) 144
South Africa: San tribe 92, 98, 101
soy, transgenic 58
Spain 147, 163
Srinivasan, C.S. 68
stem cells, human embryonic (hESCs) 145–7
Stone, G.D. 59, 65
Subramanian, A. 29
Sumitomo Chemicals 195

Svarstad, H. 60
Switzerland 33, 195, 223

Tanksley, S.D. 60
technology transfer 100, 134
Telecom Italia 116
telecommunications sector 110, 195
ETNO (European Telecommunications Network Operators Association) 116–17, 118, 120
terminator technology 60, 61, 75
Thailand: illicit seeds 58, 61
Thailand: patents and public health 29–31, 48–9
analyzing chosen events 37
Oct 2001: universal health cover 37–8
Jan 2006: mobilization 39–41
historical decision 41–3
Sept 2006: military coup 44
chain reaction 44–7
May 2007: diplomatic mission 47–8
players 32–7
Thaksin Shinawatra 32, 37, 40, 44
Thambisetty, S. 3, 215, 217, 218, 220, 224, 227, 229, 233
Thiermeyer, M. 162
Thomson, James 145
Toffler, A. 4
Tollison, R.D. 182, 186
trade associations 16–17, 22, 33
see also individual associations
traditional knowledge 35, 80–81
bio-piracy 91–2
conclusion 101–2
definitions 91–2
globalization and knowledge paradigms 81–5
Kanis: benefit sharing agreement 93–6, 101
identifying the Kanis 96–100
lessons learnt 100
key questions 85–6
nation state and IPRs 86–91, 101
nature of 88
transgenic seeds/crops see seeds, illicit
transnational corporations (TNCs) 16, 222
<table>
<thead>
<tr>
<th>Name</th>
<th>Page(s)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wasko, J.</td>
<td>162</td>
<td></td>
</tr>
<tr>
<td>Watal, J.</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Watson, D.S.</td>
<td>193</td>
<td></td>
</tr>
<tr>
<td>Watson, James</td>
<td>140</td>
<td></td>
</tr>
<tr>
<td>World Health Organization (WHO)</td>
<td>38, 42, 51</td>
<td></td>
</tr>
<tr>
<td>World Intellectual Property Organization (WIPO)</td>
<td>193, 218, 222, 224</td>
<td></td>
</tr>
<tr>
<td>copyright</td>
<td>108, 165, 166</td>
<td></td>
</tr>
<tr>
<td>indigenous people</td>
<td>85, 101</td>
<td></td>
</tr>
<tr>
<td>World Trade Organization (WTO)</td>
<td>13, 17, 31, 205</td>
<td>see also TRIPS Agreement</td>
</tr>
<tr>
<td>Zilberman, D.</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Ziltener, P.</td>
<td>173</td>
<td></td>
</tr>
<tr>
<td>Zylla, G.</td>
<td>168</td>
<td></td>
</tr>
</tbody>
</table>